Short Interest in BioVie Inc. (NASDAQ:BIVI) Declines By 29.7%

BioVie Inc. (NASDAQ:BIVI) saw a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 1,350,000 shares, a decline of 29.7% from the October 31st total of 1,920,000 shares. Based on an average trading volume of 5,610,000 shares, the short-interest ratio is presently 0.2 days. Approximately 19.6% of the shares of the stock are short sold.

BioVie Stock Up 3.3 %

BIVI traded up $0.09 during trading on Friday, hitting $2.80. The company’s stock had a trading volume of 1,098,797 shares, compared to its average volume of 1,691,573. The stock has a market capitalization of $49.76 million, a price-to-earnings ratio of -0.24 and a beta of 0.40. The firm’s 50 day moving average price is $2.27 and its two-hundred day moving average price is $1.64. BioVie has a 12 month low of $1.04 and a 12 month high of $33.10.

BioVie (NASDAQ:BIVI) last released its quarterly earnings results on Monday, September 30th. The company reported ($6.60) earnings per share (EPS) for the quarter.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.